Background: Mechanical thrombectomy is a promising adjuvant or stand-alone therapy for acute ischemic stroke (AIS) caused by occlusion of a large vessel in patients beyond the systemic thrombolysis therapeutic window. This review focuses on the clinical and angiographic outcomes of mechanical thrombectomy with use of the Merci retriever device.
IV tissue plasminogen activator (IV-tPA), despite its use since 1996 and being the only therapy approved by the US Food and Drug Administration for acute ischemic stroke (AIS), is used to treat less than 3% of patients with AIS in the United States. 1, 2 The narrow therapeutic window for systemic thrombolysis is the leading cause for treatment exclusion. 2, 3 Mechanical thrombectomy emerged as an adjuvant or stand-alone modality for AIS, and it offers some advantages over systemic thrombolysis. First, it is possible to expand the treatment window beyond the 4.5 hours given for systemic thrombolysis. Indeed, mechanical therapies were safely administered to patients within an 8-hour window in the clinical trials. 4 -6 Second, clot retrieval may provide rapid revascularization and may be more efficient with materials resistant to enzymatic degra-dation such as mature fibrin cross-linked thrombi and thrombi containing other debris such as calcium or cholesterol crystals. 7 However, the mechanical approach suffers from many technical issues, including the difficulty navigating devices into the cranial circulation and the excessive trauma to the vessels that can lead to dissection, vasospasm, or intracerebral and subarachnoid hemorrhages. Additionally, thrombus fragmentation may lead to distal embolization and subsequent ischemia in smaller and initially spared cerebral vessels. Nonetheless, mechanical approaches with little or no thrombolytic agent have emerged as a viable option for patients who have a contraindication to systemic thrombolysis, are resistant to it, or are outside the treatment time window. 8, 9 There are several options for endovascular mechanical thrombectomy; however, at the time of this review only the Merci retriever system (Concentric Medical, Mountain View, CA) and the Penumbra system (Penumbra Inc., Alameda, CA) have been approved for use in the United States. These devices have yet to be experimentally and directly compared. However, they are both used clinically and seem similarly safe and effective. In this review, we briefly describe the technical and design aspects of the Merci retriever system as well as selected outcome clinical studies using this system. THE MERCI RETRIEVER SYSTEM In 2004, the Merci retriever system was approved by the US Food and Drug Administration as the first mechanical thrombectomy device for removing clot in AIS patients. The Merci retriever has undergone considerable redesigns throughout its existence. The first generation of the retriever device (X5 and X6) boasted a corkscrew appearance due to the helical tapered fashion in which the nitinol was coiled. It was further revised and reiterated for the second generation (L4, L5, and L6) to include arcading filaments that were attached to a nontapering helical nitinol coil. The L-generation helical coil was designed in a 90-degree angle with respect to the proximal catheter. The third generation (V 2.0, V 2.5, and V 3.0) is a hybrid design of a nontapered, nonangulated filamented helical coil that was provided in soft and firm versions. The current generation is based on flexible nitinol wire that assumes a helical shape once it emerges from the tip of a microcatheter (figure 1). The helical coil loops are attached to a wire pusher and delivered through a microcatheter (18L). The system is usually used in conjunction with an 8-or 9-French balloon guide catheter. Inflating the silicone balloon at the distal end of the guide catheter temporarily arrests the antegrade flow in the carotid or the vertebral arteries and also allows for aspiration during the clot retrieval process. 10 Figure 2 demonstrates an occluded right carotid terminus
Figure 1
Merci retriever devices
The first-generation X series (A) had a tapered design without filaments. The Merci second-generation L-series (B) incorporated a "side-winder" 90-degree angle with added filaments. The Merci third-generation V series (C) is available in soft and firm configurations and incorporates a variable spring rate design along the coil for optimal clot retention. Permission to use photographs was granted by Stryker.
treated successfully with the Merci clot retrieval device.
Outcomes with the Merci retrieval system. Nearly 75% of patients with a severe stroke, exceeding 10 on the NIH Stroke Scale (NIHSS), treated with IV-tPA continue to have persisting vascular occlusions, with only 8% likelihood of significant clinical improvement. [11] [12] [13] In contrast, treatment mechanical thrombectomy devices lead to higher rates of revascularization. 8, 14, 15 It is important to note that the correlation between revascularization and good clinical outcomes has been repeatedly demonstrated. 16, 17 Given the lack of randomized control clinical efficacy trials comparing the Merci retriever to standard of care, the limited data on single-arm prospective trials, and the American Stroke Association guidelines, the level of evidence is considered less well established (Class II, level of evidence B). 18 Here we summarize the more significant studies involving the Merci retriever.
MERCI pivotal trials. Successful revascularization, measured by thrombolysis in myocardial infarction (TIMI) score of 2-3, was observed in a pilot study of 30 patients with major cerebral arterial occlusion (exceeding 10 on the NIHSS). 5 When the Merci system was used alone, 12 patients (43%) demonstrated re-vascularization. This proportion increased to 18 (64%) when intra-arterial tissue plasminogen activator (IA-tPA) was combined with the Merci device. Furthermore, 12 (43%) of the patients had asymptomatic intracerebral hemorrhage (ICH), but none were symptomatic. Significant recovery, assessed with the modified Rankin Scale (mRS score of Յ3), was demonstrated in 50% (9 of 18) and 0% (0 of 10) of revascularized and nonvascularized patients, respectively, after 1 month. A total of 10 patients (36%) died during the 30-day follow-up period; none of the deaths were related to the study device. The Mechanical Embolus Removal in Cerebral Ischemia (MERCI) and multi-MERCI trials, designed to test the safety and efficacy of the first and second generations of the retriever devices, showed similar results. 9, 15 Both trials were prospective, multicenter single-arm studies of patient populations, up to 8 hours after symptom onset, with occlusion of major cerebral blood vessel and moderate to severe stroke (NIHSS score Ն8). Patients treated with IV-tPA were included in the multi-MERCI trial. Treatable vessels included the intracranial vertebral artery, basilar artery, intracranial carotid artery, and M1 and M2 segments of the middle cerebral artery. Patients were excluded if the angiogram revealed severe arte- rial stenosis proximal to the thrombus. The rate of successful recanalization (defined as achieving TIMI 2 or 3 in all treatable vessels) and procedural safety served as the primary outcomes. Specific safety outcomes included symptomatic ICH, defined as any associated hemorrhage with clinical deterioration Ն4 points on the NIHSS, 18 mortality rate, and procedural complications. In addition, secondary outcome assessed functional recovery between the revascularized and nonrevascularized patients at day 90. A total of 141 patients were treated in the MERCI trial and 164 patients in the multi-MERCI trial. The baseline demographics, vessels treated, and safety and efficacy rates are summarized in table 1. Overall, 65% (197/305) of the patients demonstrated successful revascularization. The overall rate of favorable functional outcome (mRS Յ2) at 3 months was 32%, with a slight improvement from 28% in the MERCI trial to 36% in the multi-MERCI trial. A significantly larger proportion of revascularized than nonrevascularized patients displayed good functional outcome (48% vs 10%; relative risk, 4.98; 95% confidence interval [CI], 2.9 -8.7). Symptomatic ICH was observed in 7.8% and 9.8% of the patients enrolled in the MERCI and multi-MERCI trials, respectively. The mortality rates of the MERCI (43.5%) and multi-MERCI (34%) trials differed. It is important to note that only 28% of patients who demonstrated revascularization, compared with 53% of those who did not, died. Furthermore, logistic regression analysis of the 2 pivotal trials revealed that successful recanalization after Merci embolectomy is highly associated with favorable clinical outcome and lower mortality rate (odds ratio [OR] of 20.4 for 90-day favorable mRS; OR of 0.28 for 90-day mortality). 16 Subcohorts treated with IV-and IA-tPA. It should be noted that 29.3% of patients in the multi-MERCI trial were treated with IV-tPA. Revascularization was demonstrated in 73% of this patient population. Meanwhile, 58% of patients receiving stand-alone treatment with Merci retrievers displayed revascularization. The rate of favorable clinical outcome was 38% and the mortality rate was 29% among those treated with IV-tPA in the multi-MERCI trial. In a pooled analysis of the MERCI and multi-MERCI trials, the rate of revascularization was 73% in the IV-tPA group vs 63% in the remaining sample, with a mortality rate of 27.7% and 40.1%, respectively. However, favorable outcome was not significantly different (38% vs 31%). 19 A total of 64 patients (20.9%) had received adjuvant IA-tPA following unsuccessful recanalization with Merci embolectomy in the multi-MERCI trial. 15 Of those receiving IA-tPA, 37.5% achieved revascularization, 27.8% had a favorable functional outcome at 90 days, 10.9% had symptomatic ICH, and 46.8% died. Few conclusions can be drawn from the IV-tPAtreated cohort within the multi-MERCI trial. First, it remains unclear whether IV-tPA in combination with mechanical thrombectomy influences revascularization and clinical outcomes. Second, pretreatment with IV-tPA is relatively safe, as there were no significant differences in the rates of symptomatic ICH or clinically significant procedural complications between patients who were treated or not treated with IV-tPA.
Observational experience with the Merci retrieval system.
Twenty-five consecutive patients were treated prospectively with mechanical thrombectomy for AIS by means of the Merci retrieval system in a single-center study at the Erlanger Southeast Regional Stroke Center. 20 Inclusion and exclusion criteria for patients included in the study were similar to the criteria used in the MERCI trials. Out of the total cohort, 15 patients received adjuvant IA-TPA, 9 patients were treated within 3 hours of onset, and 8 patients had stenosis of the proximal carotid artery in excess of 50%. Fourteen patients were successfully revascularized, and only 1 patient had symptomatic ICH. The overall mortality rate was 36%, and all were nonvascularized patients. After 90 days, nearly a quarter of the patients included in the study achieved a favorable outcome. Successful revascularization occurred in half of patients with tandem lesions in the carotid and middle cerebral arteries.
Besides treating patients with tandem lesions, some institutions have used multimodal neuroimaging (CT or MRI) technology to design protocols to treat patients beyond the 8-hour symptom onset window. In a study of endovascular mechanical clot retrieval, 24 patients with relatively small established core infarcts (less than one-third of the middle cere-bral artery) and relatively large persisting salvageable ischemic penumbra (exceeding 20% of tissue) experienced cerebral blood flow of sufficient amplitude to threaten tissue integrity. 21 This study included 5 patients treated with IV-tPA and 4 patients treated outside the 8-hour window. In addition, IA-tPA was used along with platelet-disaggregating agents in revascularization failure. Within the study cohort, 54% achieved revascularization (29% partial and 25% complete revascularization) of the occluded vessel, as defined by the MERCI pivotal trials. Additionally, patients treated with only the Merci system had a revascularization rate of 63%, and 75% of patients (3/4) treated outside the 8-hour window from symptom onset achieved revascularization. Symptomatic ICH occurred in 2 patients (8.3%), both of whom underwent mechanical embolectomy with the Merci device as rescue treatment after recanalization failure with IV-tPA. Furthermore, asymptomatic ICH was reported in 38% of patients, as well as subarachnoid hemorrhage in 2 patients. Some complications were reported in the study procedure. Fracture of the coil device and detachment of the Merci retriever tip were noted in 3 patients. In 2 of those patients, the detached tips were successfully retrieved. Investigators attributed this fracture to overtorquing of the Merci device. The 90-day overall mortality rate was 29% and did not differ according to revascularization status. However, favorable clinical outcome at 90 days was clearly higher in the revascularized group (21% vs 4%). The overall favorable outcome rate was 25%. 21 The multicenter Merci registry. At the 2011 International Stroke Conference in Los Angeles, results from 872 patients treated with the Merci system in a prospective multicenter open-label registry were re- ported. 22 The study has broad inclusion criteria. Essentially, any AIS patient with a large-vessel occlusion who was treated with at least 1 pass of the Merci retriever could be included in the study, reflecting a "real world experience." The overall rate of partial or complete revascularization (thrombolysis in cerebral infarction [TICI]-2A or higher) was 80.1%. At the 90-day study outcome, close to one-third (31.6%) of patients enrolled achieved favorable clinical out-comes, and 33.4% of patients died. The overall rate of symptomatic ICH in the registry was 7%. Age and recanalization were strong predictors of clinical outcome, particularly TICI-2B and TICI-3 across all ages. Predictors of favorable outcome on multivariate analysis were younger age, lower baseline NIHSS score, successful recanalization, and lack of intubation/general anesthesia during procedure. Results from this large observational cohort on the use of the In (A), better rates of good outcome (90-day modified Rankin Scale score of Յ2) are indicated by data points farther to the right on the x-axis, whereas the converse is true for the mortality data in (B). Figure modified and reprinted 24 with permission from Springer ScienceϩBusiness Media.
Merci retrieval system are comparable to those published in pivotal MERCI trials.
COMPARING OUTCOMES WITH MERCI VS
PROACT II AND PENUMBRA Both MERCI and Penumbra pivotal trials were single-arm studies that compared outcomes with historical controls. In contrast, Prolyse in Acute Cerebral Thromboembolism (PROACT II) was a randomized clinical trial. 23 Reported rates of successful revascularization and symptomatic ICH were highest in the Penumbra trial (82% and 11.2%, respectively) and lowest in the MERCI trial (48% and 7.8%). These results are summarized in table 2. PROACT II and the multi-MERCI trial had similar rates of revascularization and symptomatic ICH: 67% and 10%, respectively. The mortality rate was higher in the MERCI (43.5%) and multi-MERCI (34%) trials and similar in the Penumbra (25%) and PROACT II (25%) trials.
Patients from the MERCI pivotal trials and PROACT II trial were carefully analyzed in a recent study (figure 3). 24 The study population was matched on age, baseline NIHSS score, and site of the arterial occlusion. The authors identified patients with AIS due to occlusion of the middle cerebral artery who were potentially eligible for inclusion in the PROACT II trial. 23, 24 A total of 141 eligible patients pooled from the MERCI pivotal trials (61 from MERCI and 80 from multi-MERCI trials) were compared with 180 patients from the PROACT II trial (59 controls and 121 prourokinase-treated patients). Notable differences in baseline characteristics of the groups were noted, such as the MERCI cohort being older and having more severe strokes, even after careful matching. As demonstrated in figure 2A , there was a trend toward better clinical outcome in the MERCI cohort vs the PROACT II control arm at 90 days (adjusted analysis: MERCI, 35.4%, p ϭ nonsignificant; multi-MERCI, 42.8%, p ϭ 0.048; PROACT II control, 25.4%). In both adjusted and unadjusted analyses, however, the mortality did not significantly differ between the MERCI and PROACT II cohorts (adjusted analysis: Abbreviations: IA ϭ intra-arterial; MCA ϭ middle cerebral artery; mRS ϭ modified Rankin Scale score; NIHSS ϭ NIH Stroke Scale score. a Abstracted from Nogueira et al., 16 with permission.
MERCI, 29.1%; multi-MERCI, 18.0%; PRO-ACT II control, 27.1%) ( figure 3 ).
DISCUSSION Several conclusions can be drawn from this review. First, the Merci system appears to be effective in retracting clots lodged in large vessels, causing devastating ischemic strokes. The relative efficacy and safety of the device have been demonstrated both in the initial MERCI trials and in subsequent observational evidence. The Merci retrieval system, according to a pooled analysis and when compared with the natural history, appears to be a safe option that may lead to better outcomes. 16 Though the revascularization rate was different in patients treated with the Merci system vs other systems, the clinical and safety outcomes were comparable. 4 It should be noted that different angiographic outcomes were used in these different trials, so comparisons about revascularization rates are unreliable at best. Second, outcomes of the MERCI trials have been reproduced by real-world evaluation of the Merci system. Third, whether or not Merci system therapy is plausible after 8 hours from symptom onset remains unclear. In fact, viable brain tissue, assessed via imaging, has been found in a recent retrospective multicenter analysis of patients who had symptoms outside the 8-hour window. 25 Merci embolectomy was performed on 62% of the patient population and elicited revascularization in 73.8%, accompanied by a symptomatic ICH rate of 8.8%. A favorable clinical outcome and mortality rate of 45% and 21.5%, respectively, was seen at day 90. Fourth, outcomes from the MERCI trials are similar to those from the PROACT II and Penumbra trials. These converging results suggest that there may be multiple viable options for the treatment of large-vessel occlusions. However, the lack of direct comparison has left practitioners in a predicament in terms of choosing the best treatment modality for revascularization. Pooling the MERCI trials made it possible to predict favorable clinical outcomes and mortality rates at day 90 after Merci treatment. Using the demographics and the site of vessel occlusion, as indicated in table 3, allowed Nogueira and colleagues 16 to suggest that revascularization was the strongest predictor of favorable functional outcome (OR 20.4; 95% CI 7.74 -53.92) and lower mortality (OR 0.28; 95% CI 0.16 -0.51). 16 In addition, favorable outcomes were more likely given a lower initial NIHSS score (OR 0.86; 95% CI 0.81-0.92) and associated with younger age (OR 0.96; 95% CI 0.95-0.98). In contrast, poor revascularization, higher NIHSS on initial presentation, older age, and occlusion at the internal carotid artery terminus were associated with higher mortality rates. The Merci retriever system was the first device approved for clot removal in AIS patients presenting with a large-vessel occlusion. Adding further credence to its efficacy are outcomes of the Merci retriever trials, comparable to those of the PROACT II and Penumbra trials. The Merci retriever is safe for treating patients presenting with moderate to large ischemic syndromes (NIHSS score Ն8) within 8 hours from symptom onset. Additional studies are necessary to investigate its use beyond the traditional time window and to fully validate its clinical efficacy against best medical treatment alone.
